Skip Navigation

Aspirin in Reducing Events in the Elderly (ASPREE)

Short Study Name (acronym): ASPREE

Long Name: Aspirin in Reducing Events in the Elderly

Investigators (list PI first):  Jeff Williamson, MD

Funding Agency: National Institute of Aging

Funding Dates: 2011 - 2015

Research questions or aims: ASPREE is a double-blind, randomized, placebo-controlled primary prevention trial designed to assess whether daily active treatment of 100 mg enteric-coated aspirin will extend the duration of disability-free life in healthy participants aged 70 years and above.  The study will examine whether the potential benefits of low dose aspirin (particularly the prevention of heart disease, stroke, certain cancers and dementia) outweigh the risks (particularly severe gastrointestinal bleeding and hemorrhagic stroke) in this age group.

Target population: Men and Women 70 years of age and older who are in good general health

Target # to enroll:


Target Dates of enrollment:

Types of assessments and questionnaires:

Study Website (if applicable):

Project Manager Contact Info: Patricia Wittmer

Last Updated: 08-19-2016
Wake Forest Baptist Ranked among Nation’s ‘Best Hospitals’  25 Years in a Row by U.S. News & World ReportComprehensive Cancer Centers National Designation is Renewed2017-2018 Best DoctorsNursing Magnet StatusJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

© Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. All Rights Reserved.